Search research articles
Contact Us
Filters
Showing results (161-170 of 383) with videos related to
Page
of 39
Sort By:
Cancer
|
August 22, 2019
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study
Elias J Jabbour, Nicola Gökbuget, Hagop M Kantarjian, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
June 30, 2011
Genetic pathways leading to therapy-related myeloid neoplasms
Angela Stoddart, Megan E McNerney, Elizabeth Bartom, et al.
Leukemia & Lymphoma
|
February 29, 2012
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study
Gerard Lozanski, Amy S Ruppert, Nyla A Heerema, et al.
Cancer Chemotherapy and Pharmacology
|
July 12, 2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
Robert E Martell, Bercedis L Peterson, Harvey Jay Cohen, et al.
Leukemia & Lymphoma
|
March 5, 2024
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy
Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, et al.
Ejhaem
|
July 18, 2022
Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults
Anand Ashwin Patel, Joseph Heng, Emily Dworkin, et al.
Blood
|
December 2, 2004
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
Joseph O Moore, Stephen L George, Richard K Dodge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia
Olatoyosi M Odenike, Serhan Alkan, Dorie Sher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2007
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study
Guido Marcucci, Kati Maharry, Susan P Whitman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2007
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
Ian W Flinn, Donna S Neuberg, Michael R Grever, et al.
Page
of 39
Search research articles
Search
Showing results (161-170 of 383) with videos related to
Sort By:
Page
of 39
Cancer
|
August 22, 2019
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study
Elias J Jabbour, Nicola Gökbuget, Hagop M Kantarjian, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
June 30, 2011
Genetic pathways leading to therapy-related myeloid neoplasms
Angela Stoddart, Megan E McNerney, Elizabeth Bartom, et al.
Leukemia & Lymphoma
|
February 29, 2012
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study
Gerard Lozanski, Amy S Ruppert, Nyla A Heerema, et al.
Cancer Chemotherapy and Pharmacology
|
July 12, 2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
Robert E Martell, Bercedis L Peterson, Harvey Jay Cohen, et al.
Leukemia & Lymphoma
|
March 5, 2024
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy
Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, et al.
Ejhaem
|
July 18, 2022
Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults
Anand Ashwin Patel, Joseph Heng, Emily Dworkin, et al.
Blood
|
December 2, 2004
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
Joseph O Moore, Stephen L George, Richard K Dodge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia
Olatoyosi M Odenike, Serhan Alkan, Dorie Sher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2007
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study
Guido Marcucci, Kati Maharry, Susan P Whitman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2007
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
Ian W Flinn, Donna S Neuberg, Michael R Grever, et al.
Page
of 39